Literature DB >> 15899840

TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1.

Florence Gizard1, Romain Robillard, Olivier Barbier, Brigitte Quatannens, Anne Faucompré, Françoise Révillion, Jean-Philippe Peyrat, Bart Staels, Dean W Hum.   

Abstract

The transcriptional regulating protein of 132 kDa (TReP-132) has been identified in steroidogenic tissues, where it acts as a coactivator of steroidogenic factor 1 (SF-1). We show here that TReP-132 plays a role in the control of cell proliferation. In human HeLa cells, TReP-132 knockdown by using small interfering RNA resulted in increased G(1)-->S cell cycle progression. The growth-inhibitory effects of TReP-132 was further shown to be mediated by induction of G(1) cyclin-dependent kinase inhibitors p21(WAF1) (p21) and p27(KIP1) (p27) expression levels. As a consequence, G(1) cyclin/cyclin-dependent kinase activities and pRB phosphorylation were markedly reduced, and cell cycle progression was blocked in the G(1) phase. The stimulatory effect of TReP-132 on p21 and p27 gene transcription involved interaction of TReP-132 with the transcription factor Sp1 at proximal Sp1-binding sites in their promoters. Moreover, in different breast tumor cell lines, endogenous TReP-132 expression was positively related with a lower proliferation rate. In addition, TReP-132 knockdown resulted in enhanced cell proliferation and lowered p21 and p27 mRNA levels in the steroid-responsive and nonresponsive T-47D and MDA-MB-231 cell lines, respectively. Finally, a statistic profiling of human breast tumor samples highlighted that expression of TReP-132 is correlated with p21 and p27 levels and is associated with lower tumor incidence and aggressiveness. Together, these results identify TReP-132 as a basal cell cycle regulatory protein acting, at least in part, by interacting with Sp1 to activate the p21 and p27 gene promoters.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15899840      PMCID: PMC1140623          DOI: 10.1128/MCB.25.11.4335-4348.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  85 in total

1.  The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy.

Authors:  G Contesso; H Mouriesse; S Friedman; J Genin; D Sarrazin; J Rouesse
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

2.  Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor.

Authors:  K B Horwitz; W L McGuire
Journal:  J Biol Chem       Date:  1978-04-10       Impact factor: 5.157

3.  A general, fast, and sensitive micromethod for DNA determination application to rat and mouse liver, rat hepatoma, human leukocytes, chicken fibroblasts, and yeast cells.

Authors:  B Fiszer-Szafarz; D Szafarz; A Guevara de Murillo
Journal:  Anal Biochem       Date:  1981-01-01       Impact factor: 3.365

4.  Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication.

Authors:  J S Meyer; B R Rao; S C Stevens; W L White
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

5.  Prognostic value of estrogen and progesterone receptors in primary breast cancer.

Authors:  S Saez; F Cheix; B Asselain
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

6.  Progesterone receptors as a prognostic factor in Stage II breast cancer.

Authors:  G M Clark; W L McGuire; C A Hubay; O H Pearson; J S Marshall
Journal:  N Engl J Med       Date:  1983-12-01       Impact factor: 91.245

7.  Identification of p34 and p13, human homologs of the cell cycle regulators of fission yeast encoded by cdc2+ and suc1+.

Authors:  G Draetta; L Brizuela; J Potashkin; D Beach
Journal:  Cell       Date:  1987-07-17       Impact factor: 41.582

8.  Standardization of steroid receptor assays in human breast cancer--IV. Long-term within- and between-laboratory variation of estrogen and progesterone receptor assays.

Authors:  A Koenders; S M Thorpe
Journal:  Eur J Cancer Clin Oncol       Date:  1986-08

Review 9.  Cell-cycle targeted therapies.

Authors:  Charles Swanton
Journal:  Lancet Oncol       Date:  2004-01       Impact factor: 41.316

10.  Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms.

Authors:  M H Kraus; N C Popescu; S C Amsbaugh; C R King
Journal:  EMBO J       Date:  1987-03       Impact factor: 11.598

View more
  9 in total

1.  TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone.

Authors:  Florence Gizard; Romain Robillard; Barbara Gross; Olivier Barbier; Françoise Révillion; Jean-Philippe Peyrat; Gérard Torpier; Dean W Hum; Bart Staels
Journal:  Mol Cell Biol       Date:  2006-10       Impact factor: 4.272

2.  MIR31HG Expression Predicts Poor Prognosis and Promotes Colorectal Cancer Progression.

Authors:  Jianlong Wang; Bin Liu; Jiewei Cao; Lianmei Zhao; Guiying Wang
Journal:  Cancer Manag Res       Date:  2022-06-16       Impact factor: 3.602

3.  Selected microRNA-192 mutant indicates association with several function genes in bovine cells.

Authors:  Chen Zi; Dexin Zeng; Jiyong Zhou; Jianjun Dai; Luyan Jiang; Feng Xue; Yuan Jiang; Baoguang Li
Journal:  Genes Genomics       Date:  2017-12-14       Impact factor: 1.839

4.  Exometabolom analysis of breast cancer cell lines: Metabolic signature.

Authors:  Lucas Willmann; Thalia Erbes; Sebastian Halbach; Tilman Brummer; Markus Jäger; Marc Hirschfeld; Tanja Fehm; Hans Neubauer; Elmar Stickeler; Bernd Kammerer
Journal:  Sci Rep       Date:  2015-08-21       Impact factor: 4.379

5.  Evolutionarily emerged G tracts between the polypyrimidine tract and 3' AG are splicing silencers enriched in genes involved in cancer.

Authors:  Muhammad Sohail; Wenguang Cao; Niaz Mahmood; Mike Myschyshyn; Say Pham Hong; Jiuyong Xie
Journal:  BMC Genomics       Date:  2014-12-19       Impact factor: 3.969

6.  Epigenetic Alterations Affecting Transcription Factors and Signaling Pathways in Stromal Cells of Endometriosis.

Authors:  Iveta Yotova; Emily Hsu; Catherine Do; Aulona Gaba; Matthias Sczabolcs; Sabine Dekan; Lukas Kenner; Rene Wenzl; Benjamin Tycko
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

7.  FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2.

Authors:  Fei Xu; Jiajia Li; Mengdong Ni; Jingyi Cheng; Haiyun Zhao; Shanshan Wang; Xiang Zhou; Xiaohua Wu
Journal:  Mol Cancer       Date:  2021-03-03       Impact factor: 27.401

8.  TdIF1 recognizes a specific DNA sequence through its Helix-Turn-Helix and AT-hook motifs to regulate gene transcription.

Authors:  Takashi Kubota; Osamu Koiwai; Katsutoshi Hori; Nobuhisa Watanabe; Kotaro Koiwai
Journal:  PLoS One       Date:  2013-07-10       Impact factor: 3.240

9.  The histone deacetylase complex MiDAC regulates a neurodevelopmental gene expression program to control neurite outgrowth.

Authors:  Baisakhi Mondal; Hongjian Jin; Satish Kallappagoudar; Yurii Sedkov; Tanner Martinez; Monica F Sentmanat; Greg J Poet; Chunliang Li; Yiping Fan; Shondra M Pruett-Miller; Hans-Martin Herz
Journal:  Elife       Date:  2020-04-16       Impact factor: 8.140

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.